Why is it that carriers have been tested for hepatitis B virus but do not need treatment? This starts with the onset of hepatitis B and the immune status of the body. As already mentioned, after the hepatitis B virus infects the body, it generally goes through four stages without external effects such as drugs. Hepatitis B virus carriers belong to the first stage – the immune tolerance period. During this period, the body’s immune monitoring system does not recognize the hepatitis B virus and mistakes it for one of its own, so it does not clear the hepatitis B virus. These viruses are free to replicate in the liver cells and do not affect the normal function of the liver cells for the time being, and the liver does not show inflammation. Just because hepatitis B carriers in the immune tolerance period, the hepatitis B virus in their bodies is more peaceful and does not provoke the liver cells, the two can live together peacefully and generally do not lead to significant liver function damage. Therefore, antiviral treatment is not needed for the time being. On the other hand, because existing drugs cannot cure the hepatitis B virus, antiviral treatment for hepatitis B carriers is not only ineffective but may also be counterproductive. There are few drugs available for the treatment of hepatitis B. There are two main categories: nucleoside analogues and interferons. After long-term treatment, the hepatitis B virus may mutate against certain nucleoside analogs and become resistant to them. When the liver develops an inflammatory response and must be treated, such drugs will not work. Ultimately, it is because the current drugs do not have the ability to cure hepatitis B. In order to avoid running out of medication when it is really needed, doctors are particularly cautious about the question of “when to start medication”.